Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Gains from Sales and Divestitures (2020 - 2025)

Terns Pharmaceuticals filings provide 5 years of Gains from Sales and Divestitures readings, the most recent being $150000.0 for Q4 2025.

  • Quarterly Gains from Sales and Divestitures fell 6.8% to $150000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $150000.0 through Dec 2025, down 6.8% year-over-year, with the annual reading at $150000.0 for FY2025, 6.8% down from the prior year.
  • Gains from Sales and Divestitures hit $150000.0 in Q4 2025 for Terns Pharmaceuticals, down from $210974.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $210974.0 in Q3 2025 and bottomed at $27055.0 in Q2 2023.
  • Average Gains from Sales and Divestitures over 4 years is $104802.3, with a median of $88952.0 recorded in 2024.
  • The largest annual shift saw Gains from Sales and Divestitures dropped 14.28% in 2021 before it skyrocketed 309.15% in 2024.
  • Terns Pharmaceuticals' Gains from Sales and Divestitures stood at $71429.0 in 2021, then dropped by 29.44% to $50401.0 in 2023, then soared by 219.31% to $160936.0 in 2024, then fell by 6.8% to $150000.0 in 2025.
  • Per Business Quant, the three most recent readings for TERN's Gains from Sales and Divestitures are $150000.0 (Q4 2025), $210974.0 (Q3 2025), and $169640.0 (Q2 2025).